221 related articles for article (PubMed ID: 27685149)
41. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
42. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
Végso G; Hajdu M; Sebestyén A
Pathol Oncol Res; 2011 Sep; 17(3):443-54. PubMed ID: 21193979
[TBL] [Abstract][Full Text] [Related]
43. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Zimmermann H; Koenecke C; Dreyling MH; Pott C; Dührsen U; Hahn D; Meidenbauer N; Hauser IA; Rummel MJ; Wolf D; Heuser M; Schmidt C; Schlattmann P; Ritgen M; Siebert R; Oschlies I; Anagnostopoulos I; Trappe RU
Leukemia; 2022 Oct; 36(10):2468-2478. PubMed ID: 35974101
[TBL] [Abstract][Full Text] [Related]
44. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
Major A; Kamdar M
Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
[TBL] [Abstract][Full Text] [Related]
45. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.
Buadi FK; Heyman MR; Gocke CD; Rapoport AP; Hakimian R; Bartlett ST; Sarkodee-Adoo C
Am J Hematol; 2007 Mar; 82(3):208-14. PubMed ID: 17022049
[TBL] [Abstract][Full Text] [Related]
46. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
[TBL] [Abstract][Full Text] [Related]
47. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S; Zecca M; Calafiore L; Rubert L; Fiocchi R; Paulli M; Quartuccio G; Guido I; Sebastiani R; Croci GA; Beschi C; Nardiello I; Ginevri F; Cugno C; Comoli P
Pediatr Transplant; 2013 Nov; 17(7):E168-73. PubMed ID: 23992468
[TBL] [Abstract][Full Text] [Related]
48. Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall.
Mohri T; Ikura Y; Hirakoso A; Okamoto M; Hishizawa M; Takaori-Kondo A; Kato S; Nakamura S; Yoshimura K; Okabe H; Iwai Y
Int J Hematol; 2018 Aug; 108(2):218-227. PubMed ID: 29380181
[TBL] [Abstract][Full Text] [Related]
49. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
50. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.
Au WY; Lie AK; Kwong YL; Shek TW; Hawkins BR; Lai KN; Tang SC; Lo CM; Fan ST; Liu CL; Chan GC; Chau EM; Chiu SW; Liang R
Leuk Lymphoma; 2002 Jul; 43(7):1403-7. PubMed ID: 12389620
[TBL] [Abstract][Full Text] [Related]
51. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres.
Santarsieri A; Rudge JF; Amin I; Gelson W; Parmar J; Pettit S; Sharkey L; Uttenthal BJ; Follows GA
Br J Haematol; 2022 May; 197(3):310-319. PubMed ID: 35235680
[TBL] [Abstract][Full Text] [Related]
52. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
[TBL] [Abstract][Full Text] [Related]
53. Lymphoma: risk and response after solid organ transplant.
Jacobson CA; LaCasce AS
Oncology (Williston Park); 2010 Sep; 24(10):936-44. PubMed ID: 21138175
[TBL] [Abstract][Full Text] [Related]
54. Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.
Tai R; Tirumani SH; Tirumani H; Shinagare AB; Hornick JL; Ramaiya NH
Br J Radiol; 2015 Aug; 88(1052):20140861. PubMed ID: 25989696
[TBL] [Abstract][Full Text] [Related]
55. High-dose Chemotherapy with Stem Cell Rescue Provided Durable Remission for Classical Hodgkin Lymphoma-type Post-transplant Lymphoproliferative Disorder after Unrelated Cord Blood Transplantation: A Case Report and Review of the Literature.
Itonaga H; Kato T; Fujioka M; Taguchi M; Taniguchi H; Imaizumi Y; Yoshida S; Miyoshi H; Moriuchi Y; Ohshima K; Miyazaki Y
Intern Med; 2017; 56(14):1873-1877. PubMed ID: 28717085
[TBL] [Abstract][Full Text] [Related]
56. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
[TBL] [Abstract][Full Text] [Related]
57. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report.
Cavaliere R; Petroni G; Lopes MB; Schiff D;
Cancer; 2010 Feb; 116(4):863-70. PubMed ID: 20052713
[TBL] [Abstract][Full Text] [Related]
58. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
59. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
60. Treatment of PTLD with rituximab or chemotherapy.
Elstrom RL; Andreadis C; Aqui NA; Ahya VN; Bloom RD; Brozena SC; Olthoff KM; Schuster SJ; Nasta SD; Stadtmauer EA; Tsai DE
Am J Transplant; 2006 Mar; 6(3):569-76. PubMed ID: 16468968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]